13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $88000 | -$14M | 0.0% | -13254.5% | — | $4M | $3M |
| 2024 | $170000 | -$17M | 0.0% | -11630.6% | -$15M | $3M | $2M |
| 2023 | $202000 | -$29M | 0.0% | -15800.0% | — | — | $5M |
| 2022 | $141000 | -$19M | 0.0% | -14129.8% | -$16M | — | $27M |
| 2021 | $135000 | -$19M | 0.0% | -13954.1% | -$14M | — | $32M |
| 2020 | $163000 | -$14M | 0.0% | -9295.7% | -$10M | $2M | $39M |
| 2019 | $140000 | -$9M | 0.0% | -8887.9% | -$9M | $2M | $1M |
| 2018 | $367000 | -$10M | 0.0% | -3132.4% | -$11M | $3M | $299000 |
| 2017 | — | -$8M | — | — | -$8M | — | $1M |
| 2016 | — | -$8M | — | — | -$8M | — | $2M |
| 2015 | — | -$15M | — | — | -$16M | — | $2M |
| 2014 | — | -$17M | — | — | -$14M | — | $2M |
| 2013 | — | -$16M | — | — | -$18M | — | $803000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $22000 | -$3M | 0.0% | -10118.2% | — | $4M | $6M |
| Dec '25 | $21000 | -$4M | 0.0% | -14057.1% | — | $4M | $3M |
| Sep '25 | $26000 | -$3M | 0.0% | -9411.5% | — | — | $2M |
| Jun '25 | $25000 | -$3M | 0.0% | -10584.0% | — | $3M | $476000 |
| Mar '25 | $16000 | -$4M | 0.0% | -22618.8% | — | $2M | $898000 |
| Dec '24 | $45000 | -$6M | 0.0% | -13011.1% | -$4M | $3M | $2M |
| Sep '24 | $35000 | -$4M | 0.0% | -12825.7% | — | $3M | $915000 |
| Jun '24 | $50000 | -$2M | 0.0% | -7388.0% | — | $3M | $4M |
| Mar '24 | $40000 | -$6M | 0.0% | -14335.0% | — | $3M | $3M |
| Dec '23 | $65000 | -$13M | 0.0% | -21544.6% | — | — | $5M |
| Sep '23 | $46000 | -$8M | 0.0% | -17732.6% | — | — | $15M |
| Jun '23 | $42000 | -$5M | 0.0% | -13002.4% | — | — | $21M |
| Mar '23 | $49000 | -$4M | 0.0% | -8765.3% | — | — | $23M |
| Dec '22 | $56000 | -$4M | 0.0% | -9921.4% | — | — | $27M |
| Sep '22 | $21000 | -$6M | 0.0% | -31052.4% | — | — | $30M |
| Jun '22 | $30000 | -$5M | 0.0% | -15650.0% | — | — | $34M |
| Mar '22 | $33000 | -$4M | 0.0% | -9551.5% | — | — | $29M |
| Dec '21 | $50000 | -$6M | 0.0% | -14890.0% | -$6M | — | $32M |
| Sep '21 | $33000 | -$4M | 0.0% | -11906.1% | -$3M | — | $37M |
| Jun '21 | $23000 | -$6M | 0.0% | -16165.2% | — | — | $41M |
How the market has priced AIM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, AIM ImmunoTech Inc.'s revenue has declined 11.6% per year. These are computed facts, not advice.
As of FY2025, AIM ImmunoTech Inc. reported $4M of total debt against $3M of cash; operating income covered interest expense -14.4×.
In FY2025, gross margin was —, operating margin -13254.5%, and net margin -15861.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.